Share

Boston Scientific Corporation (BSX.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Buy

5-Year Return Est.

+70.0%

BSX.NYSE does not currently pay dividends

1. Investment Thesis — Base Case

The central tension is that Boston Scientific lost the narrative before it lost the business. Electrophysiology and Watchman — roughly a quarter of revenue — decelerated hard, and the market repriced the entire company from a premium compounder to a low-teens forward multiple in eight months. The remaining three-quarters still compounds near 6% and generates USD 3.62B of trailing free cash flow. The base case treats 2027 as the trough, with restructuring savings, Penumbra consolidation and a dated 2027–2028 launch cadence restoring mid-single-digit organic growth, and the multiple normalising toward the low-to-mid teens rather than the discarded premium.

Adjusted path: USD 3.30 in 2026, roughly flat through 2027, approaching USD 5.00 by 2031.
A 15x exit multiple on that figure implies roughly USD 75 per share, near +70% cumulative.
Implied equity value near USD 110 billion on approximately USD 30 billion of revenue — still below the 2025 peak.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-17	44.6
Observed price	2021-10-03	42.7
Observed price	2021-10-11	42.4
Observed price	2021-10-23	44.7
Observed price	2021-11-04	43.0
Observed price	2021-11-24	39.7
Observed price	2021-11-28	38.3
Observed price	2021-12-10	41.2
Observed price	2021-12-22	42.2
Observed price	2022-01-11	43.4
Observed price	2022-01-15	44.7
Observed price	2022-01-23	42.7
Observed price	2022-02-20	43.0
Observed price	2022-02-24	44.4
Observed price	2022-03-12	41.9
Observed price	2022-03-20	44.3
Observed price	2022-04-13	44.0
Observed price	2022-04-17	45.1
Observed price	2022-04-21	46.3
Observed price	2022-05-11	38.7
Observed price	2022-05-19	39.5
Observed price	2022-05-27	41.2
Observed price	2022-06-08	38.8
Observed price	2022-06-16	36.0
Observed price	2022-07-14	37.2
Observed price	2022-07-22	38.1
Observed price	2022-07-26	39.2
Observed price	2022-08-15	42.3
Observed price	2022-08-27	40.4
Observed price	2022-09-08	42.7
Observed price	2022-09-12	43.5
Observed price	2022-09-24	38.8
Observed price	2022-10-10	39.6
Observed price	2022-10-26	41.8
Observed price	2022-10-30	43.0
Observed price	2022-11-03	41.5
Observed price	2022-11-27	43.8
Observed price	2022-12-13	47.2
Observed price	2022-12-29	46.4
Observed price	2023-01-06	45.7
Observed price	2023-01-18	45.1
Observed price	2023-01-26	46.4
Observed price	2023-02-03	48.5
Observed price	2023-02-19	46.6
Observed price	2023-02-27	46.8
Observed price	2023-03-19	48.7
Observed price	2023-03-23	48.1
Observed price	2023-04-12	51.1
Observed price	2023-04-24	51.3
Observed price	2023-05-02	52.9
Observed price	2023-05-22	53.7
Observed price	2023-05-26	51.1
Observed price	2023-06-07	50.9
Observed price	2023-06-19	54.1
Observed price	2023-06-27	53.5
Observed price	2023-07-13	52.7
Observed price	2023-07-21	53.1
Observed price	2023-08-06	50.8
Observed price	2023-08-22	50.4
Observed price	2023-08-30	54.3
Observed price	2023-09-11	54.6
Observed price	2023-09-27	52.1
Observed price	2023-10-09	52.4
Observed price	2023-10-13	49.5
Observed price	2023-10-25	50.0
Observed price	2023-11-14	54.0
Observed price	2023-11-18	54.6
Observed price	2023-11-30	55.8
Observed price	2023-12-20	55.7
Observed price	2024-01-01	57.5
Observed price	2024-01-05	58.2
Observed price	2024-01-17	61.0
Observed price	2024-01-29	61.3
Observed price	2024-02-14	66.0
Observed price	2024-02-22	66.4
Observed price	2024-03-09	67.6
Observed price	2024-03-17	67.1
Observed price	2024-03-29	68.3
Observed price	2024-04-18	67.4
Observed price	2024-04-26	73.2
Observed price	2024-05-04	72.3
Observed price	2024-05-24	75.6
Observed price	2024-05-28	75.1
Observed price	2024-06-09	77.1
Observed price	2024-06-21	77.7
Observed price	2024-07-07	76.1
Observed price	2024-07-15	78.0
Observed price	2024-08-04	73.5
Observed price	2024-08-08	75.0
Observed price	2024-08-28	80.3
Observed price	2024-09-01	81.0
Observed price	2024-09-21	83.9
Observed price	2024-09-25	83.5
Observed price	2024-10-11	87.1
Observed price	2024-10-31	84.0
Observed price	2024-11-08	88.3
Observed price	2024-11-12	88.7
Observed price	2024-12-02	90.5
Observed price	2024-12-18	89.5
Observed price	2024-12-26	91.5
Observed price	2024-12-30	89.7
Observed price	2025-01-19	99.3
Observed price	2025-01-23	101
Observed price	2025-02-12	106
Observed price	2025-02-16	106
Observed price	2025-03-08	97.5
Observed price	2025-03-12	96.4
Observed price	2025-03-24	103
Observed price	2025-04-13	94.0
Observed price	2025-04-25	101
Observed price	2025-04-29	103
Observed price	2025-05-19	106
Observed price	2025-05-27	106
Observed price	2025-06-12	98.6
Observed price	2025-06-16	101
Observed price	2025-06-28	106
Observed price	2025-07-22	103
Observed price	2025-07-30	107
Observed price	2025-08-11	103
Observed price	2025-08-23	105
Observed price	2025-09-08	108
Observed price	2025-09-16	99.2
Observed price	2025-09-24	97.9
Observed price	2025-10-06	96.3
Observed price	2025-10-14	96.3
Observed price	2025-10-26	102
Observed price	2025-11-11	103
Observed price	2025-11-23	97.7
Observed price	2025-12-01	101
Observed price	2025-12-13	92.0
Observed price	2026-01-06	97.8
Observed price	2026-01-14	93.7
Observed price	2026-01-26	93.3
Observed price	2026-02-07	75.8
Observed price	2026-02-27	76.8
Observed price	2026-03-03	73.8
Observed price	2026-03-07	72.4
Observed price	2026-03-27	69.2
Observed price	2026-04-16	64.4
Observed price	2026-04-20	60.7
Observed price	2026-04-24	64.3
Observed price	2026-05-14	52.9
Observed price	2026-05-26	57.6
Observed price	2026-06-03	47.7
Observed price	2026-06-11	47.2
Observed price	2026-07-01	43.1
Observed price	2026-07-09	45.0
Observed price	2026-07-21	43.2
Observed price	2026-07-29	46.0
Observed price	2026-08-14	51.8
Observed price	2026-08-22	49.9
Observed price	2026-09-11	43.0
Observed price	2026-09-21	43.7
Observed price	2026-09-22	44.9
Observed price	2026-09-25	43.9
Published advisor forecast	2026-09-18	43.3
Published advisor forecast	2026-12-18	42.0
Published advisor forecast	2027-03-18	43.7
Published advisor forecast	2027-06-18	45.0
Published advisor forecast	2027-09-18	45.9
Published advisor forecast	2027-12-18	47.8
Published advisor forecast	2028-03-18	50.2
Published advisor forecast	2028-06-18	52.2
Published advisor forecast	2028-09-18	53.7
Published advisor forecast	2028-12-18	55.9
Published advisor forecast	2029-03-18	58.1
Published advisor forecast	2029-06-18	59.9
Published advisor forecast	2029-09-18	61.1
Published advisor forecast	2029-12-18	62.9
Published advisor forecast	2030-03-18	64.8
Published advisor forecast	2030-06-18	66.1
Published advisor forecast	2030-09-18	67.4
Published advisor forecast	2030-12-18	69.4
Published advisor forecast	2031-03-18	70.8
Published advisor forecast	2031-06-18	72.2
Published advisor forecast	2031-09-18	73.7

2. Scenarios & Signals

Bull case

The bull case activates when share stabilises and the deal closes clean in the same six months. FARAWAVE Ultra halts pulsed-field erosion above 60% share, Penumbra consolidates without remedy, and restructuring savings arrive faster than the 2029 schedule. Each reinforces the next: restored growth rebuilds forecast credibility, credibility restores the multiple, and deleveraging frees the buyback again. At USD 5.50 of 2031 adjusted EPS on an 18x multiple, the shares approach USD 100 — a full recovery of the 2025 rating.

Bear case

The bear case activates if pulsed-field share keeps sliding while USD 11B of acquisition debt sits on the balance sheet. A third guidance cut confirms erosion is structural, Watchman stays flat, and integration costs consume the restructuring savings before they reach earnings. Leverage then constrains the buyback that has been supporting the share count, and FDA quality escalation compounds the pressure. Adjusted stalls near USD 3.00 on a 12x multiple, implying the mid-thirties — a value trap, not a recovery.

Current crowd narrative

The consensus has performed a violent role reversal: BSX went from untouchable medtech to structurally impaired share-loser in eight months, and the tape agrees — roughly 60% below the September 2025 peak with no split involved [1][2]. Sell-side models remain stale, with a USD 71.91 average target against Citi's USD 50 [15]. The anchoring bias is on electrophysiology as the whole company.

Alpha-gap assessment

The crowd underestimates these shares. The evidence chain is specific: a 17.6x trailing and roughly 13x on USD 3.28–3.32 adjusted prices Boston Scientific as an ex-growth asset, yet three-quarters of revenue still grows near 6% and trailing of USD 3.62B implies a 5.6% yield. The blind spot is composition — investors extrapolated one decelerating quarter of two franchises across a diversified portfolio. Offsetting that: USD 11B of acquisition debt and FDA quality overhang justify some discount, just not this one.

Convergence catalyst

The February 2027 fourth-quarter print, when management frames 2027 explicitly as a below-market trough year. Clearing that admitted-low bar removes the third-cut fear that dominates positioning. The first observable sign of repricing is non-electrophysiology revenue confirmed near 6% alongside restructuring savings appearing in adjusted operating margin.

Macro-regime alignment

The macro is a multiple problem here, not a revenue problem. With beta near 0.57 and procedure volumes among the least cyclical demand streams, tightening reaches Boston Scientific through the discount rate and the cost of USD 11B of acquisition debt — the Fed at 3.75–4.00% and a ten-year near 5.00% compress terminal value. Any 2028 easing cycle becomes a direct valuation tailwind.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.5
Expected volatility regime: high_erratic
Convergence-cycle position: capitulation

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
THE Seventy FIVE Percent Nobody Discusse	Interventional Cardiology, Neuromodulation and Interventional Oncology — roughly three-quarters of revenue — still compound near 6%, with Asia-Pacific operational growth of 11.2% in Q2 2026 led by Japan, China and Korea [10][17]. The market repriced the entire company on electrophysiology's stumble, yet this base generates the bulk of USD 3.62B trailing free cash flow. Procedure demand is demographically underwritten, so the cash engine persists through the narrative damage.	Not available	+25.0%
Seven Launches Already ON THE Calendar	Management dated the re-acceleration rather than merely promising it: coronary intravascular lithotripsy in H1 2027, renal denervation in 2028, FARAWAVE Ultra, FARAFLEX, intracardiac echocardiography, and TAVR re-entry via a USD 1.5B MiRus commitment [11][18]. Each attacks a market where Boston Scientific already owns the catheter-lab relationship, so incremental revenue lands at high contribution margin. Execution risk is real; the cadence itself is not speculative.	Not available	+20.0%
FIVE Hundred Million OF SELF Repair	The reorganisation targets roughly USD 500M of run-rate savings by exiting 2029, more than half by end-2027, against USD 700–800M of pre-tax charges [8][10]. Against a 2026 adjusted EPS base of USD 3.28–3.32, that saving is worth roughly USD 0.26 per share pre-tax — decisive when organic earnings growth is guided as limited. Restructuring announced under investor pressure usually lands; the charge is sunk, the savings recur.	Not available	+15.0%
Buying BACK Stock WITH BOTH Hands	Boston Scientific repurchased USD 2.00B in Q2 2026 alone against USD 282M across all of FY2025 — a seven-fold escalation executed while simultaneously funding an USD 11B cash acquisition and a restructuring charge. Trailing net buyback yield flipped to +2.26% after years of negative readings. Whether conviction or bravado, the share-count reduction mechanically compounds per-share earnings and signals insider disagreement with the tape.	Not available	+12.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Eighty Percent Share HAS ONE Direction	Boston Scientific entered 2026 holding roughly 80% of the US pulsed-field ablation market; Abbott and Johnson & Johnson took share faster than management modelled, forcing a guide to flat global electrophysiology growth in the second half [10][12]. Clinical superiority — AVANT GUARD met all endpoints [7] — does not defend price or share in a commoditising catheter category. Roughly every ten points of share is high-margin revenue that will not return.	Not available	-30.0%
Watchman's Growth Engine Seized	Left-atrial-appendage closure decelerated from roughly 30% growth to just over 4% in Q2 2026, with US standalone procedures down low-teens year over year and full-year guidance cut to flat-to-low-single-digits [10][12]. At USD 570M quarterly revenue this was among the highest-margin franchises in the portfolio. Whether the cause is concomitant-procedure mix, referral bottlenecks or competitive entry, a growth annuity has been re-rated into a mature line.	Not available	-18.0%
Eleven Billion OF DEBT INTO A FIVE Perce	The Penumbra agreement values the target at USD 14.5B, roughly 73% cash, with about USD 11B funded by new borrowing [19][21] while the US ten-year sits near 4.998% and the Fed holds 3.75–4.00%. FY2025 interest coverage of 10.7x and debt-to-equity of 0.51 both deteriorate materially post-close, and management guides USD 0.06–0.08 of first-year adjusted EPS dilution. Guidant's 2006 shadow is why the market discounts the synergy case [23].	Not available	-15.0%
Credibility IS THE Cheapest Thing TO LOS	Two consecutive 2026 guidance cuts — April's 7–8.5% growth reduced to 5.5–6.5% in July [9] — followed a February 4 disclosure that triggered securities class actions covering July 23, 2025 through February 3, 2026 [5]. Investors now treat guidance as a ceiling rather than a midpoint. Until two consecutive clean prints restore the forecast premium, the multiple stays compressed regardless of how much cash the business generates.	Not available	-12.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
PFA Share Settles Above Sixty	If FARAWAVE Ultra and FARAFLEX launch on schedule during 2027 and quarterly disclosures show US pulsed-field ablation share stabilising in the 60–70% band rather than sliding toward 40%, the central bear assumption collapses. Electrophysiology returns to high-single-digit growth by 2028, adjusted EPS re-accelerates, and the market pays a mid-to-high-teens multiple again. It stays below 50% probability because Abbott and Johnson & Johnson are funded, credentialed and now inside the same electrophysiology labs.	40.0%	+35.0%
Penumbra Closes AND Compounds	Completion during late 2026 or early 2027 without a divestiture remedy, followed by thrombectomy revenue growing above 17% under Boston Scientific's distribution, would convert the deal from a leverage overhang into a growth engine adding roughly USD 1.7B of fast-growing revenue [22]. Deleveraging then proceeds faster than modelled, restoring buyback capacity by 2028. Probability stays below half because antitrust clearance, the stockholder vote and integration of a founder-led culture are each unresolved at cutoff.	33.0%	+28.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Quality Escalation Meets Integration Failure	Boston Scientific already carries a Class I recall correction on ACCOLADE pacemakers, a Class I WATCHMAN access-system correction and a 776,000-unit Faradrive sheath recall [24][25][26]. If FDA escalates to a warning letter or consent decree during 2027–2028 while Penumbra integration consumes management bandwidth, remediation costs and shipment holds would hit the highest-margin franchises simultaneously. Probability is modest because corrections have so far been resolved through labelling and software, not manufacturing shutdown.	20.0%	-28.0%
A Third CUT Breaks THE Floor	The October 28, 2026 print already carries guidance of 3–5% growth and USD 0.80–0.82 adjusted EPS, below the indicative consensus [13]. A third consecutive reduction, or 2027 organic guidance below 4%, would confirm that electrophysiology erosion is structural rather than transitional. Forward estimates would reset toward USD 3.00, and a 12x multiple on that implies the mid-thirties. It remains under 50% because management has now guided conservatively twice and reset expectations aggressively.	35.0%	-25.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_59893325-eb53-571c-a3cd-07f59b1f14b7__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	-3.0%	42.04	The October 28 print carries third-cut risk; guidance of 3–5% growth and USD 0.80–0.82 EPS already sits below consensus. Tax-loss selling and a five-percent ten-year Treasury keep the year-end bid thin.
2	March 18, 2027	+4.0%	43.72	The fourth-quarter print frames 2027 explicitly as a below-market trough year. Clearing an admitted-low bar removes the dominant uncertainty, while Penumbra closing mechanics and early restructuring charges convert open-ended fear into a quantified floor.
3	June 18, 2027	+3.0%	45.03	Coronary intravascular lithotripsy launches in the first half, the first dated proof the pipeline cadence is real rather than rhetorical. First-quarter delivery in line with reset guidance rebuilds forecast credibility incrementally.
4	September 18, 2027	+2.0%	45.93	Summer drift dominated by electrophysiology share commentary. FARAWAVE Ultra rollout data determines whether the slide from eighty percent stabilises, while Penumbra integration costs offset early restructuring savings in reported margins.
5	December 18, 2027	+4.0%	47.77	More than half the USD 500M savings programme is targeted by end-2027; visible adjusted operating margin recovery in third-quarter numbers lifts 2028 estimates. Moderating policy-rate expectations support medtech duration.
6	March 18, 2028	+5.0%	50.16	The decisive gate: 2028 guidance is management's promised re-acceleration year, backed by seven launches and a full year of Penumbra. Credible mid-single-digit organic guidance triggers the first genuine multiple expansion.
7	June 18, 2028	+4.0%	52.17	Renal denervation launches into a large underpenetrated hypertension market. Reimbursement traction matters more than approval itself; early procedure counts and coverage decisions drive consensus estimate upgrades through the quarter.
8	September 18, 2028	+3.0%	53.73	Penumbra thrombectomy revenue consolidates at scale, lifting reported growth above organic. Free cash flow redirects toward debt paydown, and falling leverage begins dissolving the balance-sheet discount applied since the deal announcement.
9	December 18, 2028	+4.0%	55.88	Full-year delivery against 2028 guidance completes two consecutive clean prints, restoring the forecast premium investors stripped in 2026. The multiple expands toward the mid-teens on rebuilt management trust rather than new growth.
10	March 18, 2029	+4.0%	58.12	The 2029 guide confirms recovery is durable rather than a soft-comparison artefact. The final tranche of restructuring savings lands, and interest expense passes its peak as acquisition debt amortises.
11	June 18, 2029	+3.0%	59.86	Steady compounding. Electrophysiology settles at a lower but defensible share within a broader portfolio, while Asia-Pacific double-digit growth continues to carry geographic mix and offset mature US category pricing pressure.
12	September 18, 2029	+2.0%	61.06	A consolidation quarter. Resolution of the securities class actions, if reached, removes a governance overhang at modest cash cost. Valuation approaches medtech peer range, limiting further multiple-driven appreciation.
13	December 18, 2029	+3.0%	62.89	The USD 500M run-rate savings are fully realised by exiting 2029 as promised, validating operating credibility. Free cash flow conversion improves and repurchase capacity returns following the post-deal deleveraging phase.
14	March 18, 2030	+3.0%	64.77	Returns shift from multiple-driven to earnings-driven. The 2030 guide assumes mid-single-digit organic growth plus modest margin expansion; the market now pays for demonstrated delivery rather than recovery optionality.
15	June 18, 2030	+2.0%	66.07	A maturing cycle. TAVR re-entry through MiRus and next-generation pulsed-field platforms add incremental share, but the easy re-rating is behind. Price tracks underlying earnings growth with limited valuation contribution.
16	September 18, 2030	+2.0%	67.39	Competitive intensity in electrophysiology is now a permanent structural feature, capping margin upside through pricing. Cash returns increasingly substitute for growth within the total-return equation for shareholders.
17	December 18, 2030	+3.0%	69.41	The year-end guidance cycle coincides with resumed large-scale repurchases lifting per-share earnings. A lower policy-rate environment than 2026's tightening peak supports medtech valuations across the sector.
18	March 18, 2031	+2.0%	70.80	Steady execution across a mature portfolio. Incremental launches replace declining legacy lines, and the investment case is now straightforward compounding rather than the recovery trade of 2027–2028.
19	June 18, 2031	+2.0%	72.22	Mid-single-digit organic growth with modest operating leverage. Any new large debt-funded acquisition would reset the leverage debate; absent one, valuation holds near medical-device peer parity through the quarter.
20	September 18, 2031	+2.0%	73.66	Horizon close. Boston Scientific trades as a mid-teens-multiple medtech compounder with restored credibility — a normalisation of the 2026 dislocation, not a return to the 2025 premium rating.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Stock Split History – Boston Scientific | Advancing Science For Lifeinvestors.bostonscientific.com
[2]Boston Scientific - 15 Year Stock Price History | BSX | MacroTrendsmacrotrends.net
[3]BSX Stock Price Quote & News - Boston Scientificrobinhood.com
[4]Boston Scientific Corporation (BSX) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com
[5]Boston Scientific Faces Investor Lawsuit Alleging Misleading Statements About Electrophysiology Growth - TipRanks.comtipranks.com
[6]Boston Scientific (BSX) Is Down 5.8% After EP Litigation Shadows FARAPULSE Trial Data Release - What's Changed - Simply Wall St Newssimplywall.st
[7]Data at Heart Rhythm 2026 highlight key Boston Scientific therapies - Apr 26, 2026news.bostonscientific.com
[8]Boston Scientific again cuts 2026 guidance | MedTech Divemedtechdive.com
[9]Boston Scientific again cuts 2026 guidancefinance.yahoo.com
[10]What Boston Scientific’s Q2 Earnings Reveal About the EP Market’s New Competitiontikr.com
[11]Boston Scientific cuts 2026 guidance again despite Q2 beatsmassdevice.com
[12]Boston Scientific cuts guidance again after unveiling restructuring planfiercebiotech.com
[13]Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test - The Globe and Mailtheglobeandmail.com
[14]BSX Stock Quote Price and Forecast | CNNcnn.com
[15]Boston Scientific (BSX) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026public.com
[16]Boston Scientific (BSX) Q2 2026 Earnings Call Transcript - AOLaol.com
[17]Boston Scientific (BSX) Q2 2026 Earnings Call Transcript - The Globe and Mailtheglobeandmail.com
[18]Earnings call transcript: Boston Scientific cuts 2026 outlook as shares fall in Q2 2026 By Investing.cominvesting.com
[19]BOSTON SCIENTIFIC CORP - Form 8-K - FY2026sec.gov
[20]Boston Scientific announces agreement to acquire Penumbra, Inc. | Penumbra Incpenumbrainc.com
[21]Boston Scientific announces agreement to acquire Penumbra - Vascular Newsvascularnews.com
[22]Boston Scientific to acquire Penumbra for $14.5Bcardiovascularbusiness.com
[23]BOSTON SCIENTIFIC CORP - Form 425 - FY2026sec.gov
[24]FDA issues most serious recall for certain pacemaker devices by Boston Scientific | AHA Newsaha.org
[25]Steerable sheaths for PFA recalled due to safety riskcardiovascularbusiness.com
[26]Vascular Access Systems Correction: Boston Scientific Updates Use Instructions for WATCHMAN Access Systems | FDAfda.gov

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Universal Investor — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.